7.78

1.77% -0.14

After Hours: 7.80 0.02 +0.26%

Gyre Therapeutics Inc (GYRE)

Overview News Price History Why GYRE Down? Discussions Forecast

Gyre Therapeutics Inc stock is traded at $7.78, with a volume of 61,026. It is down -1.77% in the last 24 hours and up +9.27% over the past month. Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Previous Close:

$7.92

Open:

$8.02

24h Volume:

61,026

Relative Volume:

0.67

Market Cap:

$754.61M

Revenue:

$116.59M

Net Income/Loss:

$9.88M

P/E Ratio:

345.78

EPS:

0.0225

Net Cash Flow:

$-2.40M

1W Performance:

+1.43%

1M Performance:

+9.27%

6M Performance:

+5.28%

1Y Performance:

-11.69%

1-Day Range:

$7.68

$8.05

1-Week Range:

$7.30

$8.05

52-Week Range:

$6.57

$11.78

Gyre Therapeutics Inc Stock (GYRE) Company Profile

Name

Gyre Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(858) 567-7770

Address

12770 HIGH BLUFF DRIVE, SAN DIEGO

Employee

618

Twitter

Next Earnings Date

2026-05-08

Latest SEC Filings

GYRE's Discussions on Twitter

Compare GYRE vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GYRE Gyre Therapeutics Inc	7.78	768.19M	116.59M	9.88M	-2.40M	0.0225
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Initiated	Jefferies	Buy
Aug-26-25	Initiated	H.C. Wainwright	Buy
Mar-11-25	Initiated	Noble Capital Markets	Outperform
Apr-29-21	Resumed	Stephens	Overweight
Feb-10-21	Initiated	Piper Sandler	Overweight
May-21-20	Initiated	Raymond James	Outperform
Jan-04-19	Initiated	Oppenheimer	Outperform
Feb-12-18	Reiterated	B. Riley FBR, Inc.	Buy
Feb-09-18	Reiterated	Chardan Capital Markets	Buy
Dec-08-17	Initiated	B. Riley FBR, Inc.	Buy
Jun-12-17	Initiated	Chardan Capital Markets	Buy
Jun-06-17	Initiated	Ladenburg Thalmann	Buy
Jun-30-16	Initiated	Rodman & Renshaw	Buy

View All

Gyre Therapeutics Inc Stock (GYRE) Latest News

07:46 AM

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S. and China-based Fully Integrated Biopharmaceutical Company - marketscreener.com

07:46 AM

May 04, 2026

Gyre Therapeutics Acquires Cullgen in $300M All-Stock Deal to Form Fully Integrated U.S.-China Biopharma Company Focused on Fibrosis and Inflammatory Diseases - Minichart

May 04, 2026

Gyre Therapeutics Completes $300 Million All-Stock Acquisition of Cullgen - Moomoo

May 04, 2026

Gyre Therapeutics closes $300M Cullgen acquisition - Investing.com

May 04, 2026

Gyre Therapeutics Completes Cullgen Acquisition and Leadership Transition - TipRanks

May 04, 2026

Gyre Therapeutics (GYRE) closes $300M Cullgen deal, adds degrader pipeline - Stock Titan

May 04, 2026

A $300M biotech merger gives Gyre a China drug business and new CEO - Stock Titan

May 04, 2026

Gyre Therapeutics Completes Acquisition Of Cullgen To Create U.S.- And China-Based Fully Integrated Biopharmaceutical Company - TradingView

May 04, 2026

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company - Benzinga

May 04, 2026

May 01, 2026

GYRE Stock Price, Quote & Chart | GYRE THERAPEUTICS INC (NASDAQ:GYRE) - ChartMill

May 01, 2026

Apr 30, 2026

Cullgen all-stock merger and share conversion plans at Gyre (NASDAQ: GYRE) - Stock Titan

Apr 27, 2026

Apr 22, 2026

GYRE (Gyre Therapeutics Inc.) notches 10.2 percent year over year revenue growth, shares climb despite modest EPS miss.Seasonality - UBND thành phố Hải Phòng

Apr 22, 2026

GYRE (Gyre Therapeutics) Q4 2025 revenue rises 10.2 percent YoY, misses EPS estimates as shares fall 2.28 percent.Margin Improvement - Xã Vĩnh Công

Apr 22, 2026

Apr 18, 2026

Gyre Therapeutics (GYRE) Stock Cancelled Order (Bullish Momentum) 2026-04-18Institutional Flow - Cổng thông tin điện tử Tỉnh Sơn La

Apr 18, 2026

Apr 17, 2026

Form 8-KCurrent report - ADVFN

Apr 17, 2026

Form 424B3Prospectus [Rule 424(b)(3)] - ADVFN

Apr 17, 2026

Form S-3Registration statement under Securities Act of 1933 - ADVFN

Apr 17, 2026

Form SC 13D/AGeneral statement of acquisition of beneficial ownership: [Amend] - ADVFN

Apr 17, 2026

Form 424B5Prospectus [Rule 424(b)(5)] - ADVFN

Apr 17, 2026

Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - ADVFN

Apr 17, 2026

[8-K/A] GYRE THERAPEUTICS, INC. Amends Material Event Report - Stock Titan

Apr 17, 2026